OOIR: Observatory of International Research

Papers

(The median citation count of Cancer and Metastasis Reviews is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	382
Clonal tracking in cancer and metastasis	261
The functions and modifications of tRNA-derived small RNAs in cancer biology	253
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions	166
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities	148
Regulation of dormancy during tumor dissemination: the role of the ECM	133
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms	121
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?	86
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression	86
CAR T-cell therapy to treat multiple myeloma: current state and future directions	75
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer	68
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?	67
p73 isoforms meet evolution of metastasis	62
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives	61
Cell-cell interactions mediating primary and metastatic breast cancer dormancy	61
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond	53
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review	50
Preface	46
Biography—Mathieu Boissan, Pharm.D., Ph.D	46
Neuropeptide Y in cancer—biological functions and potential clinical implications	45
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	45
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance	43
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy	43
Biographies	43
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications	43

The role of cancer cell bioenergetics in dormancy and drug resistance	42
Tumor necrosis factor superfamily signaling: life and death in cancer	38
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development	38
Clusterin: a marker and mediator of chemoresistance in colorectal cancer	38
Short-chain fatty acids in cancer pathogenesis	38
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy	38
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions	37
Clinical interventions to break the obesity and cancer link: a narrative review	37
The emerging roles of histone demethylases in cancers	36
Vaping and tumor metastasis: current insights and progress	36
Carcinoma of unknown primary (CUP): an update for histopathologists	35
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy	34
Kenneth V. Honn, Ph.D. (1946–2023)	33
Functional and clinical roles of stromal PDGF receptors in tumor biology	33
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution	32
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape	31
OX40/OX40 ligand and its role in precision immune oncology	31
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases	30
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy	30
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect	29
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting	29
New progress of tuberculosis scar carcinoma	28
HOXA9 transcription factor is a double-edged sword: from development to cancer progression	28
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics	28
Ferroptosis: iron release mechanisms in the bioenergetic process	28
Is cancer an intelligent species?	28
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases	28
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies	28
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment	28
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs	27
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets	27
Metastasis suppressor genes and their role in the tumor microenvironment	27
Metastasis suppressor genes in clinical practice: are they druggable?	26
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets	26
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer	25
The diversity of natural killer cell functional and phenotypic states in cancer	25
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer	24
The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers	24
Role of myeloid-derived suppressor cells in tumor recurrence	24
Lost at SCLC: a review of potential platinum sensitizers	24
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy	24
Preface	23
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis	23
Biography—Mikhail Kolonin	23
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma	23
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors	21
Biographies	21
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics	21
White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions	21
Multiomics approach towards characterization of tumor cell plasticity and its significance in precision and personalized medicine	21

Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?	21
Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance	21
The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin	20
Epigenetic control of pancreatic cancer metastasis	20
Epigenetic drugs in cancer therapy	20
Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies	20
Potential biomarkers for immunotherapy in non-small-cell lung cancer	20
The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response	19
Insights into the role of senescence in tumor dormancy: mechanisms and applications	19
Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings	19
Natural compounds targeting nuclear receptors for effective cancer therapy	19
Minimally invasive biomarkers for triaging lung nodules—challenges and future perspectives	19
Epigenetic markers and therapeutic targets for metastasis	18
Preface	18
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance	18
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response	18
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance	18
Oral delivery of RNAi for cancer therapy	18
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases	17
Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies	17
Glioblastoma stem cell metabolism and immunity	16
Advancements in gene therapies targeting mutant KRAS in cancers	16
Evolving strategies for addressing CAR T-cell toxicities	16
Epigenetic changes and the dynamic heterogeneity of the metastatic phenotype – challenges ahead	15
Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art	15
Recapitulating the potential contribution of protein S-palmitoylation in cancer	15
Retraction Note: EET signaling in cancer	15
Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma	15
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance	15
The fibro-adipogenic progenitor APOD+DCN+LUM+ cell population in aggressive carcinomas	15